China Post Securities released a research report on April 26 stating that it gave Maipu Medical (301033.SZ) a purchase rating. The main reasons for the rating include: 1) the company achieved sales revenue of 69.667 million yuan in 2023, an increase of 61.13% over the same period last year; 2) in 2023, more than 100,000 tablets of absorbable regenerated cellulose oxide hemostasis products were used clinically at home and abroad; 3) the company actively participated in the bidding process related to dural medical glue in 2023; 4) the company actively deployed domestic and overseas medical device markets. (Mainichi Keizai Shimbun)
中邮证券4月26日发布研报称，给予迈普医学（301033.SZ）买入评级。评级理由主要包括：1）2023年公司颅颌面修补及固定系统实现销售收入6,096.67万元，比上年同期增长61.13%；2）2023年可吸收再生氧化纤维素止血产品在海内外临床使用超过100,000片；3）2023年公司积极参与硬脑膜医用胶相关的招投标工作；4）公司积极布局国内和海外医疗器械市场。（每日经济新闻）
China Post Securities released a research report on April 26 stating that it gave Maipu Medical (301033.SZ) a purchase rating. The main reasons for the rating include: 1) the company achieved sales revenue of 69.667 million yuan in 2023, an increase of 61
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.